

Docket No. 0933-0185P

REMARKS

The specification has been amended to provide a cross-reference to the previously filed International Application.

The amendment to the claims is merely to correct improper multiple dependencies and to place the application into better form for examination. Entry of the above amendments is earnestly solicited. An early and favorable first action on the merits is earnestly solicited.

Attached hereto is a marked-up version of the changes made to the application by this Amendment.

If necessary, the Commissioner is hereby authorized in this, concurrent, and future replies, to charge payment or credit any overpayment to Deposit Account No. 02-2448 for any additional fees required under 37 C.F.R. § 1.16 or under 37 C.F.R. § 1.17; particularly, extension of time fees.

Respectfully submitted,

BIRCH, STEWART, KOLASCH & BIRCH, LLP

By 

Gerald M. Murphy, Jr., #28,977

P.O. Box 747
Falls Church, VA 22040-0747
(703) 205-8000

GMM/cgc
0933-0185P

Attachment: VERSION WITH MARKINGS TO SHOW CHANGES MADE

(Rev. 02/21/02)

Docket No. 0933-0185P

VERSION WITH MARKINGS TO SHOW CHANGES MADE

The claims have been amended as follows:

4. (Amended) The oligosaccharides according to claim 1[, 2 or], characterized in that monosaccharide 1 is Glc or GlcNAc.

16. (Amended) The process according to [any one of claims 13 to 15]claim 13, characterized in that the donor nucleotide sugar containing L-fucose is GDP-L-fucose.

17. (Amended) The process according to [any one of the claims 14 to 16]claim 14, characterized in that the fucosyltransferase is human α 1-3/4fucosyltransferase or α 1-3/4 fucosyltransferase III-VII, IX or α 1-3/ α 1-3/4fucosyltransferase of human milk.

18. (Amended) The process according to [any one of the preceding claims 13 to 17]claim 13, characterized in that it comprises the further step of reacting the product obtained with the formula I with β -N-acetyl-hexosaminidase.

(Rev. 11/13/01)